Positive interim result reported in study of SurVaxM in glioblastoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MimiVax LLC announced positive interim results from a multicenter phase II study of SurVaxM in patients with newly diagnosed glioblastoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login